Table 1. National database analysis of surgical cases of SCLC by the 7th TNM classification.
| Authors and journal | Database | Year | N | c-stage (%) | p-stage (%) | 5-year survival range (%) | Comments |
|---|---|---|---|---|---|---|---|
| Vallières et al., J Thorac Oncol [2009] (4) | IASLC | 1990−2000 | 349 | IA =34%; IB =25%; IIA =4%; IIB =9%; IIIA =21%; IIIB =5%; IV =2% | IA =22%; IB =22%; IIA =12%; IIB =9%; IIIA =21%; IIIB =11%; IV =3% | pIA =56%; pIB =57%; pIIA =38%; pIIB =40%; pIIIA =12%; pIIIB =0% | 19.7% of cI−II upstaged to pIIIA; NA regarding to adjuvant therapy |
| Yu et al., J Thorac Oncol [2010] (6) | SEER | 1988−2004 | 1,560 | ND | I =100% | LB with RT =57.1%; LB without RT =49.1%; P=0.90 | No CT data on SEER |
| Weksler et al., Ann Thorac Surg [2012] (7) | SEER | 1988−2004 | 895 | I =76%; II =24% | ND | 34 months of MST; Survival advantage of surgery in cI−II | No survival improvement in addition of RT |
| Takei et al., J Thorac Oncol [2014] (23) | JLCR | 2004 | 243 | IA =54.3%; IB =14.3%; IIA =10.3%; IIB =4.1%; IIIA =12.3%; IIIB =1.2%; IV=2.9% | IA =38.3%; IB =21.0%; IIA =11.1%; IIB =7.0%; IIIA =18.5%; IIIB =0.4%; IV =3.7% | pIA =72.3%; pIB =61.1%; pIIA =44.8%; pIIB =40.3%; pIIIA =23.4%; pIIV =0% | 23.2% of cIAB upstaged p-stage II or III. No survival improvement in addition of adjuvant CT |
| Thomas et al., Lung Cancer [2017] (24) | NCDB | 2004−2013 | 477 | IA =84.2%; IB =16.8% | Same stage =52%; upstage =36%; P<0.01 |
25% of cIAB upstaged p-stage II or III. Survival improvement of additional CT/RT in upstage cases |
IASLC, International Association for the Study of Lung Cancer; SEER, Surveillance Epidemiology and End Results; JLCR, Japanese Lung Cancer Registry; LB, lobectomy; RT, radiation; CT, chemotherapy; ND, no data; NA, no analysis.